Clinical Trials Using Anti-IL-8 Monoclonal Antibody HuMax-IL8

Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-IL-8 Monoclonal Antibody HuMax-IL8. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-6 of 6
  • A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

    The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
    Location: 7 locations

  • Nivolumab and Degarelix with or without BMS-986253 in Treating Patients with Hormone-Sensitive Prostate Cancer

    This phase Ib / II trial studies the side effects and how well nivolumab and degarelix with or without BMS-986253 work in treating patients with prostate cancer that is sensitive to hormone therapy. Immunotherapy with monoclonal antibodies, such as nivolumab and BMS-986253, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Testosterone can cause the growth of prostate cancer cells. Drugs, such as degarelix, may lessen the amount of testosterone made by the body. It is not yet known whether giving nivolumab and degarelix with or without BMS-986253 will work better in treating patients with hormone-sensitive prostate cancer.
    Location: 4 locations

  • Nivolumab with or without BMS-986253 for the Treatment of Advanced Liver Cancer

    This phase II trial studies how well nivolumab with or without BMS-986253 works in treating patients with liver cancer that has spread to other places in the body (advanced). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Monoclonal antibodies, such as BMS-986253, may interfere with the ability of tumor cells to grow and spread. Giving nivolumab with BMS-986253 may work better in treating patients with liver cancer compared to nivolumab alone.
    Location: 2 locations

  • Nivolumab in Combination with BMS-986253 or Cabiralizumab Before Surgery for the Treatment of Newly Diagnosed Surgically Resectable, Recurrent or Metastatic Head and Neck Cancer, SPARK2 Study

    This phase II trial studies the effect of nivolumab given in combination with BMS-986253 or cabiralizumab before surgery in treating patients with squamous cell cancer of the head and neck that is newly diagnosed and can be removed by surgery (surgically resectable), has come back (recurrent), or has spread to other places in the body (metastatic). Nivolumab is an antibody (a type of human protein) type of immunotherapy that is being tested to see if they will allow the body’s immune system to work against tumor cells. The immune system is the way the body fight infections such as cold and flu, however, its role in stopping the development and growth of cancer cells is just as important. Immune cells produced in the body recognize both infectious cells and cancer cells as foreign and the immune system is constantly watching out for these threats and killing them before they can threaten our health. BMS-986253 and cabiralizumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. Giving nivolumab together with BMS-986253 or cabiralizumab before surgery may induce response (shrinkage) of the tumor in patients with head and neck cancer.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Anti-IL-8 (BMS-986253) for Hospitalized Patients with COVID-19

    This phase II trial investigates how well BMS-986253 works in treating hospitalized patients with severe COVID-19. COVID-19 is a highly contagious respiratory disease caused by the SARS-CoV-2 virus. The primary causes of death in patients infected with SARS-CoV-2 is acute respiratory distress syndrome, which is primarily a process mediated by molecules promoting inflammation that in turn leads to profound lung injury. BMS-986253 is a human monoclonal antibody against the inflammation promoting mediator called interleukin-8 (IL-8), with potential antineoplastic activities. BMS-986253 may help to improve the outcome of COVID-19 patients.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • Nivolumab and BMS-813160 or BMS-986253 for the Treatment of Resectable Non-small Cell Lung Cancer or Liver cancer

    This phase II trial studies how well nivolumab given together with BMS-813160 or BMS-986253 before surgery work in treating patients with non-small cell lung cancer or liver cancer that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies such as nivolumab may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with BMS-986253 and BMS-813160 may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab with BMS-813160 or BMS-986253 before surgery may work better in treating patients with non-small cell lung cancer or liver cancer compared to nivolumab alone.
    Location: Icahn School of Medicine at Mount Sinai, New York, New York